Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$31.56 USD
-1.11 (-3.40%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $31.53 -0.03 (-0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CORT 31.56 -1.11(-3.40%)
Will CORT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Other News for CORT
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Interesting CORT Put And Call Options For February 2025
Corcept Therapeutics (CORT) Gets a Buy from Truist Financial
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions